EASL Recommendations on Treatment of Hepatitis C 2015.

Jean-Michel PAWLOTSKY, A Aghemo, D Back, G Dusheiko, X Forns, M Puoti, C Sarrazin,

J Hepatol 01/07/2015;63(1) : 199-236 10.1016/j.jhep.2015.03.025 21/04/2015

Spectrum of adult Parvovirus B19 infection according to the underlying predisposing condition and proposals for clinical practice.

A Wolfromm, Christophe RODRIGUEZ, M Michel, A Habibi, V Audard, E Benayoun, Olivier ROGIER, Dominique CHALLINE, O Chosidow, JD Lelievre, X Chevalier, F Le Bras, C Pautas, M Imbert, Jean-Michel PAWLOTSKY, O Wagner-Ballon,

Br J Haematol. 01/07/2015;170(2) : 192-199 10.1111/bjh.13421 28/04/2015

Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.

S Larrat, S Vallet, S David-Tchouda, A Caporossi, J Margier, C Ramiere, C Scholtes, S Haim-Boukobza, AM Roque-Afonso, B Besse, E Andre-Garnier, S Mohamed, P Halfon, A Pivert, H Le Guillou-Guillemette, F Abravanel, M Guivarch, V Mackiewicz, O Lada, T Mourez, JC Plantier, Y Baazia, S Alain, S Hantz, V Thibault, C Gaudy-Graffin, D Bouvet, A Mirand, C Henquell, J Gozlan, G Lagathu, C Pronier, A Velay, E Schvoerer, P Trimoulet, H Fleury, Magali BOUVIER-ALIAS, E Brochot, G Duverlie, S Maylin, S Gouriou, Jean-Michel PAWLOTSKY, P Morand,

J Clin Microbiol. 01/07/2015;53(7) : 2195-2202 10.1128/JCM.03633-14. 29/04/2015

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.

Christophe RODRIGUEZ, C Soulie, AG Marcelin, V Calvez, D Descamps, C Charpentier, P Flandre, P Recordon-Pinson, P Bellecave, Jean-Michel PAWLOTSKY, B Masquelier,

PLoS One. 11/06/2015;10(6) : e0127816 10.1371/journal.pone.0127816.

Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication.

A Florimond, P Chouteau, Patrice BRUSCELLA, J Le Seyec, E Merour, Nazim AHNOU, A Mallat, S Lotersztajn, Jean-Michel PAWLOTSKY,

Gut. 01/06/2015;64(6) : 957-965 10.1136/gutjnl-2013-305634. 25/07/2014

From non-A, non-B hepatitis to hepatitis C virus cure

Jean-Michel PAWLOTSKY, JJ Feld, S Zeuzem, JH Hoofnagle,

J Hepatol. 01/04/2015;62(1 Suppl) : S87-99 10.1016/j.jhep.2015.02.006.

Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014.

Jean-Michel PAWLOTSKY,

Gastroenterology 01/03/2015;148(3) : 468-479 10.1053/j.gastro.2015.01.002 07/01/2015

Viral entry inhibition: too late for hepatitis C, but promising for other viral infections.

Jean-Michel PAWLOTSKY,

Gut. 01/03/2015;64(3) : 362-364 10.1136/gutjnl-2014-307452. 06/08/2014

Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful

Isaac RUIZ, Cyrille FERAY, Jean-Michel PAWLOTSKY, Christophe HEZODE,

Liver Transpl. 01/03/2015;21(3) : 408-409 10.1002/lt.2405 20/01/2015

Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy.

C Sarrazin, H Wedemeyer, G Cloherty, DE Cohen, Stephane CHEVALIEZ, C Herman, B Bernstein, Jean-Michel PAWLOTSKY,

J Virol Methods. 01/03/2015;214 : 29-32 10.1016/j.jviromet.2014.11.027 18/12/2014